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E-mail address: lucilia.saraiva@ff.up.pt (L. Saraiva)The complexity of the mammalian p53 pathway and protein kinase C (PKC) family has hampered the
discrimination of the effect of PKC isoforms on p53 activity. Using yeasts co-expressing the human
wild-type p53 and a mammalian PKC-a, -d, -e or -f, we showed a differential regulation of p53 activ-
ity and phosphorylation state by PKC isoforms. Whereas PKC-a reduced the p53-induced yeast
growth inhibition and cell cycle arrest, PKC-d and -e enhanced the p53 activity through p53 phos-
phorylation, and PKC-f had no effect on p53. This work identiﬁed positive and negative p53 regula-
tors which represent promising pharmacological targets in anti-cancer therapy.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The p53 tumour suppressor protein is mutated in about half of
all human tumours and in many others that retain a wild-type
(WT) p53, p53-dependent pathways leading to cell cycle arrest or
cell death are often deﬁcient. Restoring p53 function represents
therefore a promising approach for cancer therapeutics. Among
the different mechanisms of p53 regulation, post-translational
modiﬁcation by phosphorylation has been shown to play a critical
role in the stabilization and activation of WT p53 [1].
One of the key enzymes involved in p53 phosphorylation is pro-
tein kinase C (PKC) [2,3]. PKC is a family of serine/threonine ki-
nases with at least 10 isoforms grouped into three subfamilies
based on their primary structure and cofactors required for activa-
tion: classical (a, bI, bII and c), novel (d, e, g and h) and atypical (f
and k=i). PKC isoforms are important regulators of several cellular
processes, such as cell proliferation and death, and a striking fea-
ture is that individual isoforms can exert either similar or opposite
effects in these processes [4,5].chemical Societies. Published by E
opidium iodide; OD, optical
species; WT, Wild-type
.Due to the high complexity of the mammalian p53 pathway and
PKC family, particularly the coexistence of several PKC isoforms in
the same cell, discrimination of the role of each PKC isoform in the
regulation of p53 activity has been hampered. To circumvent this
limitation, in this work, we exploited yeast cells co-expressing
the human WT p53 and an individual mammalian PKC isoform.
The remarkably high degree of conservation of many pathways
and cellular processes among yeast and human has allowed trans-
posing the knowledge obtained in yeast to mammalian cells and
vice versa. Additionally, the data obtained with the expression of
human proteins that lack a yeast orthologue have been crucial to
elucidate the role of proteins and the molecular mechanisms of
complex human disorders, such as cancer and neurodegenerative
diseases [6]. Since the yeast PKC (Pkc1p in Saccharomyces cerevisiae)
is a structural but not a functional homologue of mammalian PKC
isoforms, yeast was considered a well-suited organism to study
individual mammalian PKC isoforms [7]. Indeed, the yeast PKC as-
say has been used by us to search for isoform-selective PKC modu-
lators [8] and to study the regulation of human apoptotic proteins
by PKC isoforms [9]. Similarly, though no orthologues of human
p53 have been identiﬁed in yeast, S. cerevisiae has been extensively
used to score several functional properties of human p53 [10].
The yeast expression systems established in this study allowed
investigating the existence in yeast of a molecular mechanismlsevier B.V. All rights reserved.
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isoforms and WT p53. The results obtained underscore a differen-
tial regulation of p53 activity by PKC isoforms with the identiﬁca-
tion of kinases responsible for both a positive and negative
regulation of p53.
2. Materials and methods
2.1. Plasmids
Constructed yeast expression plasmids YEplac181-LEU2 encod-
ing bovine PKC-a, rat PKC-d, mouse PKC-e or PKC-f and the
empty vector, and pLS89-TRP1 encoding human WT p53 and
the empty vector, were kindly provided by Dr. Nigel Goode (TheC
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Fig. 1. WT p53-induced yeast growth inhibition is differently regulated by PKC isoforms
45 h incubation; value of yeast co-expressing p53 and a PKC isoform signiﬁcantly differen
the growth of co-transformed cells for 45 h incubation; value obtained with RO 32-043
values were obtained considering the growth achieved with control yeast (YEplac181 +Royal Veterinary College, UK) and Dr. Richard Iggo (Swiss Insti-
tute for Experimental Cancer Research, Switzerland), respectively.
Plasmids used have a galactose-inducible GAL1-10 promoter.
2.2. Yeast strain, transformation and growth conditions
S. cerevisiae CG379 was co-transformed by the lithium acetate
method, as reported [9]. For selection of co-transformed yeasts,
cells were routinely grown in a minimal selective medium, with
2% glucose, 0.67% yeast nitrogen base without amino acids and
all the amino acids required for yeast growth (50 lg/ml) except
leucine and tryptophan, to approximately 1 optical density
(OD)600. To induce expression of mammalian proteins, yeasts were
diluted to 0.05 OD600 in selective medium with 2% galactose and0
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Fig. 2. Expression of humanWT p53 or a mammalian PKC isoform is not affected by co-expression of both proteins in yeast. Western blot analysis of (A, B) p53, (C) PKC-a, (D)
PKC-d, (E) PKC-e and (F) PKC-f represent 1 of duplicate experiments; b-actin was used as loading control. (G, H) Quantiﬁcation of band intensities of Western blots obtained
for (G) p53 and (H) PKC isoforms; data represent means ± S.E.M. (n = 2).
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r.p.m.) for up to 60 h in growth curves experiments, or for approx-
imately 45 h (time required by control yeast, co-transformed with
the empty vectors pLS89 and YEplac181, to achieve 0.5 OD600) in
all other experiments. Yeast growth was analysed by counting
the number of colony-forming units per ml (CFU/ml) after 2 days
incubation at 30 C on Sabouraud Dextrose Agar plates.
2.3. Effect of the selective PKC inhibitor Ro 32-0432 on yeast growth
To analyse the effect of Bisindolylmaleimide XI hydrochloride
(Ro 32-0432; ALX-270-058, Alexis Biochemicals) on yeast growth,
co-transformed cells were incubated in galactose selective medium
with 1 lM Ro 32-0432 or solvent only (0.1% DMSO) for approxi-
mately 45 h, at 30 C with shake (200 r.p.m.). Yeast growth was
analysed as described above.
2.4. Cell death markers
Plasma membrane integrity and DNA fragmentation were ana-
lysed by ﬂuorescence microscopy using propidium iodide (PI) and
In Situ Cell Death Detection Kit, Fluorescein, respectively, whereas
yeast metacaspase (Yca1p) activation and reactive oxygen species
(ROS) accumulation were analysed by ﬂow cytometry using FITC-
VAD-fmk and dihydroethidium (DHE), respectively, as described
[8].
2.5. Cell cycle
Flow cytometric analysis of DNA content was performed using
Sytox Green Nucleic Acid, as described [8]. Yeast cell cycle phaseswere identiﬁed and quantiﬁed using ModFit LT software (Verity
Software House Inc., Topsham, USA).
2.6. Western blot
For human WT p53 and mammalian PKC isoforms detection,
anti-p53 (DO-1) and anti-PKC-a/PKC-d/PKC-e/PKC-f mouse mono-
clonal antibodies (Santa Cruz Biotechnology) were used. p53 phos-
phorylation was analysed using phospho-p53(Ser15) mouse
monoclonal antibody, phospho-p53(Ser20) and phospho-
p53(Ser46) rabbit polyclonal antibodies (Cell Signaling Technol-
ogy), and PAb421 mouse monoclonal antibody (Calbiochem). The
etoposite-treated MCF7 cell lysate (sc-2281; Santa Cruz Biotech-
nology) was used as positive control. Immunoblots were developed
by enhanced chemiluminescence, as described [9]. Band intensities
were quantiﬁed using Bio-Proﬁl Bio-1D++ software.
2.7. Statistical analysis
Data were analysed statistically using SigmaStat 3.5 pro-
gramme. Differences between means were tested for signiﬁcance
using the unpaired Student’s t-test (P 6 0.05).3. Results
3.1. Differential regulation of WT p53-induced yeast growth inhibition
by PKC isoforms
In accordance with other authors [11,12], we veriﬁed that
expression of human WT p53 in S. cerevisiae inhibited cell growth
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Fig. 3. Effects of WT p53 and/or a PKC isoform on yeast growth are not associated with cell death. (A) Cells with DNA fragmentation (TUNEL+) and necrotic cells (PI+) obtained
from yeast expressing WT p53 for 35, 45 and 60 h incubation; (B) TUNEL and PI positive cells, (C) Yca1p activation and (D) ROS accumulation, obtained from yeast expressing
WT p53 and/or a PKC isoform for 45 h incubation. In B, C and D, yeasts expressing PKC-e treated with 1 lM coleon U (see [8]) were used as positive control (C+). Data
represent means ± S.E.M. (n = 2); values signiﬁcantly different from control yeast (YEplac181 + pLS89): *P < 0.05.
I. Coutinho et al. / FEBS Letters 583 (2009) 3582–3588 3585(Fig. 1A and B). Instead, and as previously reported by us [8,9], in
our experimental conditions expression of a mammalian PKC iso-
form did not signiﬁcantly interfere with yeast growth (Fig. 1A
and B). However, when PKC-a, -d, -e or -f was co-expressed with
p53, a differential regulation of p53-induced growth inhibition
by PKC isoforms was obtained (Fig. 1A and B). This was particularly
evident for 45 h incubation (Fig. 1B). For this time, whereas PKC-a
signiﬁcantly reduced the p53-induced growth inhibition, PKC-d
and -e signiﬁcantly increased the p53 growth-inhibitory effect
and PKC-f did not interfere with the p53 effect.
The direct effect of PKC isoforms on p53 was evidenced using
the selective PKC inhibitor Ro 32-0432. Though 1 lM Ro 32-0432
did not signiﬁcantly interfere with the growth of yeasts expressing
p53 or a PKC isoform only, it signiﬁcantly reduced the effects
exhibited by PKC-a, -d and -e on p53 activity (Fig. 1C).
As conﬁrmed by Western blot analysis, this distinct inﬂuence of
each PKC isoform on p53 effect was not a consequence of signiﬁ-
cant changes in the expression levels of p53 or a PKC isoform in
yeast co-expressing both proteins (Fig. 2).
3.2. WT p53 yeast growth-inhibitory effect and its stimulation by PKC-
d and -e are not associated with cell death
A recent work associated the human WT p53 growth-inhibitory
effect to the induction of an apoptotic cell death in S. cerevisiae
[11]. Hence, typical necrotic and apoptotic markers, as loss of plas-
ma membrane integrity, DNA fragmentation, ROS accumulation
and Yca1p activation, were investigated.
However, in our experimental conditions, expression of human
WT p53 in yeast did not signiﬁcantly increase the PI and TUNELpositive cells (Fig. 3A and B), Yca1p activation and ROS levels
(Fig. 3C and D). Even in the presence of a PKC isoform, particularly
PKC-d or -e, characteristic features of cell death were not detected
(Fig. 3B–D). Indeed, though yeast co-expressing p53 and PKC-e pre-
sented a signiﬁcant increase in ROS levels, this was not accompa-
nied by an increase of PI and TUNEL positive cells and Yca1p
activation (Fig. 3B–D).
According to Amor et al. [11], a complete abolishment of yeast
growth associated with cell death can be achieved using a multi-
copy vector for p53 expression and minimal medium culture con-
ditions that rendered yeasts more responsive to target gene
regulation by p53. In fact, similarly to that obtained by us, Nigro
et al. [12] only observed a modest yeast growth inhibition using a
centromeric low-copy-number vector for p53 expression. How-
ever, considerable levels of p53 expression were also achieved
in our work using a pLS89 centromeric vector (Fig. 2A and B).
Additionally, a minimal medium similar to that described by
Amor et al. [11] was used in our study. In order to understand
the different results obtained, co-transformed yeasts expressing
WT p53 only (YEplac181 + p53) were treated with different con-
centrations of hydrogen peroxide (a known yeast apoptotic indu-
cer, see [13]). In accordance with the high-level resistance to cell
death detected in a previous work performed by us with co-trans-
formed yeasts [9], a signiﬁcant percentage of TUNEL positive cells
(21.3 ± 5.4%; n = 3), with a low percentage of IP positive cells
(9.2 ± 4.1%; n = 3), was only achieved at high concentrations of
hydrogen peroxide (10 mM H2O2, 1 h treatment). Thus, the use
of co-transformed yeast strains with high-level resistance to cell
death may be a possible explanation for the results obtained by
us.
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cell cycle arrest that is differently regulated by PKC isoforms
As in mammalian cells, where p53 controls cell cycle mainly
through the G1/S checkpoint [2], we detected that p53-induced
yeast growth inhibition was associated with S-phase cell cycle ar-
rest (Fig. 4). Instead, and in agreement with the absence of effect
on yeast growth, PKC isoforms only slightly interfered with the
yeast cell cycle progression (Fig. 4). However, when PKC-a, -d,
-e or -f was co-expressed with p53, a speciﬁc PKC isoform-depen-
dent modulation of cell cycle through p53 was obtained (Fig. 4).
Whereas PKC-a decreased the percentage of cells in S-phase
and increased the percentage of cells in G2/M, PKC-d and -e
markedly increased the percentage of cells arrested in S-phase.
Consistently, PKC-f that did not affect the p53-induced growth
inhibition also did not interfere with the p53-induced S-phase
arrest.
3.4. Differential regulation of p53 effects by PKC isoforms is associated
with distinct patterns of p53 phosphorylation in yeast
Phosphorylation of WT p53 at commonly reported p53 phos-
phorylation sites, Ser15, Ser20, Ser46 and Ser376-378 [2,3,14],
was checked by Western blot analysis. p53 phosphorylation at
Ser15, Ser20 and Ser46, analysed using a phospho-p53 antibodyspeciﬁc for each serine, was not detected neither in yeast express-
ing p53 only nor in yeast co-expressing p53 and a PKC isoform
(Fig. 5A–C). p53 phosphorylation at Ser376-378 was analysed
using the PAb421 antibody which preferentially recognizes
unphosphorylated p53 residues at Ser376-378. Indeed, it was dem-
onstrated that when p53 was phosphorylated at Ser376-378 by
PKC the PAb421 band almost disappeared [3]. In our case, a high
intensity PAb421 band was obtained for yeast expressing p53 only
(Fig. 5D and E), indicating the absence of p53 phosphorylation at
Ser376–378 by endogenous yeast kinases. This band was therefore
used as control. Interesting, when compared to control band,
whereas PKC-a slightly decreased and PKC-f did not interfere with
the PAb421 band intensity, PKC-d and -e markedly decreased the
intensity of this band (Fig. 5D and E). This indicated that, while
PKC-a and -f did not signiﬁcantly interfere with the degree of
p53 phosphorylation, PKC-d and -e markedly increased p53
phosphorylation.
Overall, despite phosphorylation of human WT p53 by endoge-
nous kinases was already reported for S. cerevisiae [12], to our
knowledge the sites of p53 phosphorylation were still unclear.
The results obtained indicated that p53 is not phosphorylated at
Ser15, Ser20, Ser46 and Ser376-378 by yeast kinases. Importantly,
though p53 phosphorylation by PKC has been described at distinct
serine residues [2,3,14], in yeast we only detected phosphorylation
at Ser376–378, which is the most commonly reported PKC
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due, a PKC isoform-dependent phosphorylation pattern was
identiﬁed.
4. Discussion
The involvement of PKC family in the regulation of cell prolifer-
ation was early recognized. While PKC-a and -f are frequently
associated to the proliferation of human cancers and PKC-d is often
linked to an anti-proliferative effect [4,5], PKC-e has been associ-
ated both to proliferative [4,5] and anti-proliferative [15] effects.
In spite of this, the molecular mechanism of induction or suppres-
sion of cell proliferation by PKC isoforms remains unclear. Another
open issue is the role of PKC isoforms in the regulation of p53, a key
player in cell proliferation and death. The PKC-mediated effects are
in fact largely tissue and cell-type-speciﬁc, thus it has been difﬁcult
and controversial to extrapolate conclusions from one mammalian
cell type to another.
This study represents the ﬁrst attempt to reconstitute in yeast
key parts of the intricate mammalian p53-PKC network. With this
yeast approach, it was possible to ascertain the effect of individual
PKC isoforms, representative of the classical (PKC-a), novel (PKC-d
and -e) and atypical (PKC-f) PKC subfamilies and considered major
isoforms in carcinogenesis, cell proliferation and human WT p53activity. The results obtained revealed that even though the PKC
isoforms per se had no effect on yeast growth and cell cycle, they
differentially interfered with the p53-induced yeast growth inhibi-
tion and cell cycle arrest and p53 phosphorylation. They under-
scored an anti-proliferative effect of PKC-d and -e through
phosphorylation and consequent activation of p53. In opposition,
they evidenced a proliferative effect of PKC-a through inhibition
of p53 function. Further studies are underway to better elucidate
the molecular mechanism of this PKC-a-inhibitory effect. Finally,
the absence of effect of PKC-f on the activity and phosphorylation
state of p53 indicated that p53 was not a target of this kinase.
As a whole, this study established a unifying mechanism be-
tween the modulation of cell proliferation by PKC-a, -d and -e
and the regulation of p53. For PKC-f, a p53-independent effect on
cell proliferation was suggested. Additionally, it underscored a dif-
ferential regulation of p53 activity and phosphorylation state by
PKC isoforms, with the identiﬁcation of kinases responsible for
both a positive and negative regulation of p53. These kinases rep-
resent therefore promising molecular and pharmacological targets
in anti-cancer therapy. As reported by others, the distinct roles of
individual PKC isoforms in cancer progression suggests that either
PKC activators or inhibitors may serve as anti-tumour agents if tar-
get speciﬁc members of the PKC family [5]. Accordingly, our data
support that selective PKC-a inhibitors as well as selective PKC-d
3588 I. Coutinho et al. / FEBS Letters 583 (2009) 3582–3588and -e activators may be beneﬁcial in the therapy of several can-
cers by inhibiting the proliferation particularly of those tumours
where PKC-a is up-regulated and PKC-d or -e are down-regulated.
This study will certainly contribute to the elucidation of the effect
of PKC activators and inhibitors on tumour cells proliferation, pro-
viding new perspectives for PKC modulators as anti-cancer agents.
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